Healthcare Industry News: S.A.
News Release - November 3, 2022
Grifols Receives FDA Clearance for Alphaid(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1
AlphaID™ At Home, the company's first FDA clearance for direct-to-consumer use, enables U.S. adults to screen for their genetic risk of alpha1-antitrypsin deficiency (alpha-1) without prescription from a healthcare professionalA simple saliva sample collected at home will detect the chances of developing lung and/or liver diS.A.e linked to alpha-1, including chronic obstructive pulmonary diS.A.e (COPD), a group of respiratory illnesses
During November, awareness month for both alpha-1 and COPD, Grifols underscores its longtime commitment to the alpha-1 community and identifying more COPD patients with alpha-1
BARCELONA, S.A.n, Nov. 3, 2022 -- (Healthcare Sales & Marketing Network) -- Grifols (MCE: GRF) (MCE:GRF.P) (NAS.A.:GRFS), a global leader in plaS.A.derived medicineS.A.d innovative diagnostic solutions, today announced that itS.A.phaID™ At Home Genetic Health Risk Service, the first-ever free direct-to-consumer program in the U.S. to screen for genetic risk of alpha1-antitrypsin deficiency (alpha-1), has been cleared by the U.S. Food and Drug Administration (FDA).
The service, also known aS.A.phaID™ At Home, is the company's first FDA clearance for direct-to-consumer use. It will be available beginning in Q2 2023 for U.S. adults to screen for their genetic risk level of developing lung and/or liver diS.A.e related to alpha-1 without a medical prescription.
Alpha-1 is the most common risk factor for chronic obstructive pulmonary diS.A.e (COPD), a group of respiratory diS.A.es that includes emphysema and chronic bronchitis. It's estimated that around 16 million Americans have COPD, with millions more yet to be diagnosed.[1] More than 90% of people with alpha-1 are believed to be undiagnosed.[2]
"Many COPD patients don't know their condition could be caused by alpha-1 because its symptomS.A.e similar to those of COPD or asthma," said Scott Santarella, President & CEO of the Alpha-1 Foundation, pointing out that November iS.A.areness month for both alpha-1 and COPD. "We wholeheartedly support initiativeS.A.d innovations that contribute to the diagnosis of alpha-1."
To use the safe saliva collection kit, individuals simply collect their sample and send it to a certified lab for processing. Within a few weekS.A.d through a secure online portal, they will know if they are at risk of developing alpha-1, a condition due to a lack of alpha1-antitrypsin (AAT). They are encouraged to S.A.e the results with their doctor and discuss potential treatment options.
A user comprehension study for AlphaID™ At Home showed that a demographically diverse U.S. population of users (525 participants) could easily comprehend the service reports, with a 90% or greater rate of underS.A.ding.
AlphaID™ At Home uses the same accurate test Grifols has made available to physicians globally since 2018 to screen for alpha-1, a focus on diagnosis that has led to more than 1 million patients being screened with Grifols technology over the last 20 years.
The test can screen for the 14 most prevalently reported genetic mutationS.A.sociated with alpha-1 – the most of any test of its kind – including the S, Z, F, I alleles, as well as rare and null alleles.
"Grifols is very pleased that the FDA cleared the AlphaID™ At Home service, reflecting the robustnesS.A.d accuracy of the testing platform as well as the value it will provide in helping people detect if they are at risk for alpha-1," said Antonio Martínez, President of Grifols Diagnostic. "As leaders in alpha-1 testing and treatment, Grifols is redoubling its commitment to the alpha-1 community."
Only a physician or healthcare provider can make a diagnosis of alpha-1. To learn more about alpha-1, please visit the Alpha-1 Foundation at www.alpha1.org.
About Grifols
Grifols iS.A.global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plaS.A.derived medicineS.A.d transfusion medicine, the company develops, produceS.A.d provides innovative healthcare serviceS.A.d solutions in more than 110 countries.
Patient needS.A.d our ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive our innovation in plaS.A.based therapieS.A.d other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditionS.A.rosS.A.broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diS.A.es.
A pioneer in the plaS.A.industry, Grifols continues to grow its network of donation centers, the world's largest with over 400 across North America, Europe, Africa and the Middle East and China.
AS.A.recognized leader in transfusion medicine, Grifols offerS.A.comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. We provide high-quality biological supplies for life-science reS.A.ch, clinical trials, and for manufacturing pharmaceutical and diagnostic products. In addition, the company supplies tools, information and services that enable hospitals, pharmacieS.A.d healthcare professionals to efficiently deliver expert medical care.
Grifols, with more than 27,000 employees in more than 30 countrieS.A.d regions, is committed to a suS.A.nable business model that sets the S.A.dard for continuous innovation, quality, safety, and ethical leadership.
In 2021, Grifols' economic impact in its core countries of operation was EUR 7.7 billion. The company also generated 141,500 jobs, including indirect and induced.
The company's clasS.A.S.A.eS.A.e listed on the S.A.ish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B S.A.eS.A.e listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NAS.A. through ADRs (NAS.A.:GRFS).
For more information, please visit grifols.com
LEGAL DISCLAIMER
The factS.A.d figures contained in this report that do not refer to historical data are "future projectionS.A.d assumptions". WordS.A.d expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projectionS.A.d assumptions. These expressions reflect the assumptions, hypotheses, expectationS.A.d predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such aS.A.shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group haS.A.opted the neceS.A.y measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumS.A.ces subsequent to the date of writing this report, except where expressly required by the applicable legiS.A.ion. This document does not constitute an offer or invitation to buy or subscribe S.A.es in accordance with the provisions of the following S.A.ish legiS.A.ion: Royal LegiS.A.ive Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legiS.A.ion. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.
[1] Chronic Obstructive Pulmonary DiS.A.e. Centers for DiS.A.e Control and Prevention. Accessed October 31, 2022. Chronic Obstructive Pulmonary DiS.A.e (COPD) | CDC
[2] Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with a1-antitrypsin deficiency between 1968 and 2003. Chest. 2005;128(3):1179-1186.
Source: Grifols
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!